These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12270728)

  • 1. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen.
    Lavigne MV; Castro M; Mateo N; Deluchi S; Atzori C; Piudo L; Calcagno M; Brero ML; Manghi M
    Microbes Infect; 2002 Jul; 4(8):815-20. PubMed ID: 12270728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response.
    Lavigne MV; Castro M; Andino J; Manghi M
    Microbes Infect; 2004 Apr; 6(5):481-4. PubMed ID: 15109963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of chosen parameters of immuno response in mice immunized with whole-cell or acellular pertussis vaccines and challenged with B. pertussis strains harbouring different ptxS1/prn allele genes combinations].
    Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
    Med Dosw Mikrobiol; 2007; 59(2):137-47. PubMed ID: 17929411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice.
    Ryan M; Gothefors L; Storsaeter J; Mills KH
    Dev Biol Stand; 1997; 89():297-305. PubMed ID: 9272363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
    Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
    Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytokines induced by experimental anti-tetanus immunization. Vaccine formulation effect].
    Castro M; Mateo N; Lavigne V; Deluchi S; Atzori C; Piudo L; Brero ML; Manghi M
    Medicina (B Aires); 2002; 62(2):154-8. PubMed ID: 12038038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0.
    Barnard A; Mahon BP; Watkins J; Redhead K; Mills KH
    Immunology; 1996 Mar; 87(3):372-80. PubMed ID: 8778021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a new enhanced tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine against Bordetella pertussis in a murine model.
    Kang KR; Huh DH; Kim JA; Kang JH
    BMC Immunol; 2021 Oct; 22(1):68. PubMed ID: 34641798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
    Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
    J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative trial to assess the reactogenicity of the diphtheria-tetanus-acellular pertussis (DTPa) vaccine plus Haemophilus influenzae type B (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib conjugate vaccine, administered in single injection a.
    Calbo F; Dal-Ré R; Díez-Delgado J; Oña S; Sánchez-Prados F; García-Corbeira P;
    Med Clin (Barc); 2002 Jan; 118(1):1-4. PubMed ID: 11803003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to a Tdap booster in vertically HIV-infected adolescents.
    Spina FG; Gouvea A; Succi RCM; Calanca F; Weckx LY; Terreri MT; Takano MAS; de Moraes-Pinto MI
    Vaccine; 2018 Sep; 36(37):5609-5616. PubMed ID: 30087050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
    Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
    Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
    Tran Minh NN; He Q; Ramalho A; Kaufhold A; Viljanen MK; Arvilommi H; Mertsola J
    Pediatrics; 1999 Dec; 104(6):e70. PubMed ID: 10586004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
    Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
    Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.